Drug delivery approaches to overcome bacterial resistance to β-lactam antibiotics

Expert Opinion on Drug Delivery

Volumn 5, Issue 9, 2008, Pages 931-949

  Abeylath, Sampath C ^a   Turos, Edward ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

lactamases; lactams; Antibiotic resistance; Drug delivery; Nanoparticles; Penicillin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; CLOXACILLIN; FLEROXACIN DEACETYLCEFOTAXIME ESTER; IMIPENEM; LIPOSOME; MEROPENEM; METICILLIN; MONOBACTAM DERIVATIVE; NAFCILLIN; NANOPARTICLE; NOCARDICINIC ACID DERIVATIVE; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIVAMPICILLIN; SULBACTAM; SULTAMICILLIN; TAZOBACTAM; UNINDEXED DRUG; BETA LACTAM; DRUG CARRIER; PRODRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL CELL WALL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BIOFILM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENCAPSULATION; HUMAN; INTRACELLULAR KILLING; NANOPHARMACEUTICS; NONHUMAN; PENICILLIN RESISTANCE; PLASMA HALF LIFE; REVIEW; SALMONELLOSIS; STAPHYLOCOCCUS INFECTION;

BETA-LACTAM RESISTANCE; BETA-LACTAMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; NANOPARTICLES; PRODRUGS;

EID: 54049106971     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.9.931     Document Type: Review

References (113)

1. Broccolo F, Cainelli G, Caltabiano G, et al. Design, synthesis, and biological evaluation of 4-alkyliden-β-lactams: new products with promising antibiotic activity against resistant bacteria. J Med Chem 2006;49:2804-11
2. Wilke MS, Lovering AL, Natalie CJ, Strynadka NCJ. β-lactam antibiotic resistance: a current structural perspective. Curr Opin Microbiol 2005;8:525-33
3. Dantzig AH. Oral absorption of β-lactams by intestinal peptide transport proteins. Adv Drug Deliv Rev 1997;23:63-76
4. Waxman DJ, Strominger JL. Sequence of active site peptides from the penicillin-sensitive D-alanine carboxypeptidase of Bacillus subtilis. J Biol Chem 1980;255:3964-76
5. Frere JM, Nguyen-Disteche M, Coyette J, Joris B. Interaction with the penicillin binding proteins. In: Page, MI, editor, The chemistry of β-lactams. Blackie Academic and Professional, NewYork; 1992. p. 148-97
6. Ghuysen JM, Charlier P, Coyette J, et al. Penicillin and beyond: evolution, protein fold, multimodular polypeptides, and multiprotein complexes. Microb Drug Resist 1996;2:163-75
7. Goffin C, Ghuysen JM. Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol Mol Biol Rev 1998;62:1079-93
8. Kotra LP, Mobashery S. β-lactam antibiotics, β-lactamases and bacterial resistance. Bull Inst Pasteur 1998;96:139-50
9. Knowles JR. Penicillin resistance: the chemistry of β-lactamase inhibition. Acc Chem Res 1985;18:97-104
10. Therrien C, Levesque RC. Molecular basis of antibiotic resistance and β-lactamase inhibition by mechanism-based inactivators: perspectives and future directions. FEMS Microbiol Rev 2000;24:251-62
11. Chambers HF. Methicillin-resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997;10:781-91
12. Klevins RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-71
13. Mukhopadhyay S, Chakrabarti P. Altered permeability and β-lactam resistance in a mutant of Mycobacterium smegmatis. Antimicrob Agents Chemother 1997;41:1721-4
14. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001;47:247-50
15. Babic M, Hujer AM, Bonomo RA. What's new in antibiotic resistance? Focus on β-lactamases. Drug Res Updates 2006;9:142-56
16. Adam D. β-lactam/β-lactamase inhibitor combinations in empiric management of pediatric infections. J Int Med Res 2002;30(Suppl 1):10A-19A
17. Adam D. β-lactam antibiotics: their role in the management of infections in children. Pediatr Infect Dis J 1998;17:S4-S7
18. Moosdeen F. Impact of β-lactamases on the clinical use of β-lactam antibiotics. In: Viewpoints in medicine, countering resistance due to β-lactamases. Worthing: Cambridge Medical Publications; 1996. p. 6-11
19. Moosdeen F. The evolution of resistance to cephalosporins. Clin Infect Dis 1997;24:487-93
20. Livermore DM. Bacterial resistance to carbapenems. Adv Exp Med Biol 1995;390:25-47
21. Rolinson GN. Evolution of β-lactamase inhibitors. Rev Infect Dis 1991;13:S727-32
22. Brown AG, Corbett DF, Eglington AJ, Howarth. Structures of olivanic acid derivatives MM 4550 and MM 13902;two new, fused β-lactams isolated from Streptomyces olivaceus. J Chem Soc Chem Commun 1977;523-5
23. Reading C, Cole M. Clavulanic acid: a β-lactamase inhibiting β-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977;11:852-857
24. Wildfeuer A, Rader K. Stability of β-lactamase inhibitors and β-lactam antibiotics in parenteral dosage forms and in body fluids and tissue homogenates: a comparative study of sulbactam, clavulanic acid, ampicillin and amoxicillin. Int J Antimicrob Agents 1996;6:S31
25. Grimm H. Comparative in vitro studies on the β-lactamase-inhibiting effect of clavulanic acid and sulbactam on ampicillin-resistant Enterobacteriaceae, Int J Antimicrob Agents 1996;6:S9
26. Lee N, Yuen KY, Kumana CR. Clinical role of β-lactam/ β-lactamase inhibitor combinations. Drugs 2003;63:1511-24
27. Buynak JD. Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitor combinations. Biochem Pharmacol 2006;71:930-40
28. Martinez JL, Vicente MF, Delgado-Iribarren A, et al. Small plasmids are involved in amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother 1989;33:595
29. Wu PJ, Shannon K, Phillips I. Effect of hyperproduction of TEM-1 β-lactamase on in vitro susceptibility of Escherichia coli to β-lactam antibiotics. Antimicrob Agents Chemother 1994;38:494-8
30. Wu PJ, Shannon K, Phillips I. Mechanisms of hyperproduction of TEM-1 β-lactamase by clinical isolates of Escherichia coli. J Antimicrob Chemother 1995;36:927-39
31. Reguera JA, Baquero F, Perez-Diaz JC, Martinez JL. Factors determining resistance to β-lactam combined with blactamase inhibitors in Escherichia coli. J Antimicrob Chemother 1991;27:569-75
32. Bonomo RA, Rice LB. Inhibitor resistant class A β-lactamases. Front Biosci 1999;4:34-41
33. Nicolas-Chanoine MH. Inhibitor-resistant β-lactamases. J Antimicrob Chemother 1997;40:1-3
34. Chaibi EB, Sirot D, Paul G, Labia R. Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999;43:447-58
35. Yang Y, Rasumussen BA, Shlaes DM. Class A β-lactamases: enzyme-inhibitor interactions and resistance. Pharmacol Ther 1999;83:141-51
36. Yoshimura F, Nikaido H. Diffusion of β-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob Agents Chemother 1985;27:84-92
37. Hakimelahi GH, Shia K, Xue C, et al. Design, synthesis, and biological evaluation of a series of β-lactam-based prodrugs. Bioorg Med Chem 2002;10:3489-98
38. Kazmierczak A, Cordin X, Jduez JM, et al. Differences between clavulanic acid and sulbactam in induction and inhibition of cephalosporinases in enterobacteria. J Int Med Res 1990;18:D67-77
39. Livermore DM, Akova M, Wu PJ, Yang YJ. Clavulanate and β-lactamase induction. J Antimicrob Chemother 1989;24(Suppl B):23-33
40. Li Q, Lee JY, Castillo R, et al. NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against β-lactamase-producing strains. Antimicrob Agents Chemother 2002;46:1262-8
41. Stone GW, Zhang Q, Castillo R, et al. Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by β-lactamases. Antimicrob Agents Chemother 2004;48:477-83
42. Wang Y, Lambart P, Zhao L, Wang D. Synthesis and antibacterial activity of dual-action agents of a β-lactam antibiotic with cytotoxic agent mitozolomide or temozolomide. Eur J Med Chem 2002;37:323-32
43. Hakimelahi GH, Moosavi-Movahedi AK, Saboury AA, et al. Carbapenem-based prodrugs. Design, synthesis, and biological evaluation of carbapenems. Eur J Med Chem 2005;40:339-49
44. Carryn S, Chanteux H, Seral C, et al. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin N Am 2003;17:615-34
45. Carryn S, Van Bambeke F, Mingoet-Leclercq MP, Tulkens PM. Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. J Antimicrob Chemother 2003;51:1051-2
46. Lemaire S, Van Bambeke F, Mingoet-Leclercq MP, Tulkens PM. Activity of three β-lactams (entrapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J Antimicrob Chemother 2005;55:897-904
47. Lemaire S, Bambeke FV, Mingeot-Leclercq MP, et al. Carbapenems are active against intracellular MRSA [abstract A-1832]. 45th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC; 2005
48. Lemaire S, Van Bambeke F, Mingoet-Leclercq MP, et al. Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin. Antimicrob Agents Chemother 2007;51:1627-32
49. Chanteux H, Mingoet-Ledercq MP, Sonoveaux E, et al. Intracellular accumulation and activity of ampicillin used as free drug and as its phthalimidomethyl or pivaloyloxymethyl ester (pivampicillin) against Listeria monocytogenes in J774 macrophages. J Antimicrob Chemother 2003;52:610-5
50. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-1822
51. Soppimath KS, Aminabhavi TM, Kulkami AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20
52. Ravi Kumar MNV. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 2000;3:234-5
53. Williams J, Lansdown R, Sweitzer R, et al. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release 2003;91:167-72
54. Fernandez-Urrusuno R, Fattal E, Rodrigues JM, et al. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J Biomed Mater Res 1996;31:401-8
55. Lobenberg R, Kreuter J. Macrophage targeting of azidothymidine:a promising strategy for AIDS therapy. AIDS Res Hum Retroviruses 1996;12:1709-15
56. Reilly RM, Sandhu J, Alvarez-Diez TM, et al. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28:126-42
57. Chun L. Poly(L-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev 2002;54:695-713
58. Elizabeth R, Gillies J, Frechet MJ. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005;10:35-43
59. Huwyler J, Wu D, Paradridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996;93:14164-9
60. Uekama K, Otagiri M. Cyclodextrins in drug carrier systems Crit Rev Ther Drug Carrier Syst 1987;3:1-40
61. Venier-Julienne MC, Benoit JP. Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm Acta Helv 1996;71:121-8
62. Risbud MV, Hardikar AA, Bhat SV, Bhode RR. pH-sensitive freeze-dried chitosan-polyvinyl pyrrolidone hydrogels as controlled release system for antibiotic delivery. J Control Release 2000;68:23-30
63. Martens PJ, Bryant SJ, Anseth KS. Tailoring the degradation of hydrogels formed from multivinyl poly(ethylene glycol) and poly(vinyl alcohol) macromers for cartilage tissue engineering. Biomacromolecules 2003;4:283-92
64. Changez M, Koul V, Dinda AK. Efficacy of antibiotics-loaded interpenetrating network (IPNs) hydrogel based on poly(acrylic acid) and gelatin for treatment of experimental osteomyelitis: in vivo study. Biomaterials 2005;26:2095-104
65. Kreuter J. Nanoparticle-based drug delivery systems. J Control Release 1991;16:169-76
66. Couvreur P, Fattal E, Alphandary H, et al. Intracellular targeting of antibiotics by means of biodegradable nanoparticles. J Control Release 1992;19:259-67
67. Jani P, Halbert W, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989;41:809-12
68. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed Nanotechnol Biol Med 2006;2:8-21
69. Kuo PL, Turro NJ, Tseng CH, et al. Photoinitiated polymerization of styrene in microemulsions. Macromolecules 1987;20:1216-21
70. Huguette PA, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents 2000;13:155-68
71. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 1990;42:821-6
72. Jani P, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989;41:809-12
73. Cui Z, Mumper RJ. The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses. Eur J Pharm Biopharm 2003;55:11-8
74. Kreuter J, Speiser PP. New adjuvants on a poly(methyl methacrylate) base. Infect Immun 1976;13:204-10
75. Couvreur P, Kante B, Roland M, et al. Polycyano acrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol 1979;31:331-2
76. Vauthier C, Dubernet C, Fattal E, et al. Poly(alkyl cyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 2003;55:519-48
77. Velaga SP, Ghaderi R, Carlfors J. Preparation and characterisation of hydrocortisone particles using a supercritical fluids extraction process. Int J Pharm 2002;231:155-66
78. Cavallaro GM, Fresta G, Giammona G, Villari PA. Entrapment of β-lactams antibiotics in polyethylcyanoacrylate nanoparticles: studies on the possible in vivo application of this colloidal delivery system. Int J Pharm 1994;111:31-41
79. Fattal E, Youssef M, Couvreur P, Andremont A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob Agents Chemother 1989;33:1540-3
80. 3H)ampicillin-loaded nanoparticles J Antimicrob Chemother 1996;37:105-15
81. Fontana G, Pitarresi G, Tomarchio V, et al. Preparation, characterization and in vitro antimicrobial activity of ampicillin-loaded poly(ethyl cyanoacrylate) nanoparticles. Biomaterials 1998;19:1009-17
82. Fontana G, Licciardi M, Mansueto S, et al. Amoxicillin-loaded poly(ethyl cyanoacrylate) nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 2001;22:2857-65
83. Turos E, Reddy GSK, Greenhalgh K, et al. Penicillin-bound polyacrylate nanoparticles: restoring the activity of β-lactam antibiotics against MRSA. Bioorg Med Chem Lett 2007;17:3468-72
84. Diilen K, Weyenberg Vandervoort J, Ludwig A. The influence of the use of viscosifying agents as dispersion media on the drug release properties from PLGA nanoparticles. Eur J Pharm Biopharm 2004;58:539-49
85. Prior S, Gamazo C, Irache JM, et al. Gentamicin encapsulation in PLA/ PLGA microspheres in view of treating Brucella infections. Int J Pharm 2000;196:115-25
86. Santos-Magalhaes NS, Pontes A, Pereira VMW, Caetano MNP. Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules. Int J Pharm 2000;208:71-80
87. Taton AT, Mirkin CA, Letsinger RL. Scanometric DNA array detection with nanoparticle probes. Science 2000;289:1757-60
88. Prime KL, Whitesides GM. Self-assembled organic monolayers: model systems for studying adsorption of proteins at surfaces. Science 1991;252:1164-767
89. Diaz HVR, Batdorf KH, Fianchinin M, et al. Antimicrobial properties of highly fluorinated silver(I) tris(pyrazolyl)borates. J Inorg Biochem 2006;100:158-60
90. Balogh L, Swanson DR, Tomalia DA, et al. Dendrimer-silver complexes and nanocomposites as antimicrobial agents. Nano Lett 2001;1:18-21
91. Ramstedt M, Cheng N, Azzaroni O, et al. Synthesis and characterization of poly(3-sulfopropylmethacrylate) brushes for potential antibacterial applications. Langmuir 2007;23:3314-21
92. Kong H, Jang J. Antibacterial properties of novel poly(methyl methacrylate) nanofiber containing silver nanoparticles. Langmuir 2007;24:2051-6
93. + in Vibrio cholerae. Antimicrob Agents Chemother 2002;46:2668-70
94. Panacek A, Kvitek L, Prucek R, et al. Silver colloid nanoparticles: synthesis, characterization, and their antibacterial activity. J Phys Chem B 2006;110:16248-53
95. Li P, Li J, Wu C, et al. Synergic antibacterial effects of β-1actam antibiotic combined with silver nanoparticles. Nanotechnology 2005;16:1912-7
96. De Souza A, Mehta D, Leavitt RW. Bactericidal activity of combinations of silver-water dispersion with 19 antibiotics against seven microbial strains. Curr Sci 2006;91:926-9
97. Gu H, Ho PL, Tong E, et al. Presenting vancomycin on nanoparticles to enhance antimicrobial activities. Nano Lett 2003;3:1261-3
98. Tom RT, Suryanarayanan V, Reddy PG, et al. Ciprofloxacin-protected gold nanoparticles. Langmuir 2004;20:1909-14
99. Goodman CM, Mccusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem 2004;15:897-900
100. Chen JF, Ding HM, Wang JX, Shao L. Preparation and characterization of porous hollow silica nanoparticles for drug delivery application. Biomaterials 2004;25:723-7
101. Yoshida T, Qin L, Linda AE, Masayori I. Transcription regulation of ompF and ompC by a single transcription factor, OmpR. J Biol Chem 2006;281:17114-23
102. Raja SB, Murali MR, Devaraj SN. Differential expression of ompC and ompF in multidrug-resistant Shigella dysenteriae and Shigella flexneri by aqueous extract of Aegle marmelos, altering its susceptibility toward β-lactam antibiotics. Diagn Micro Infect Dis 2008; In press
103. Davies TA, Page MG, Shang W, et al. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 2007;51:2621-4
104. Lodisea TP, Patela N, Renaud-Mutarta A, et al. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn Microb Infect Dis 2008; In press
105. Turos E, Konaklieva MI, Ren Rxf, et al. N-Thiolated bicyclic and monocyclic β-lactams. Tetrahedron 2000;56:5571-8
106. Turos E, Konaklieva MI, Coates C, et al. N-Thiolated β-lactams: novel antibacterial agents for methicillin-resistant Staphylococcus aureus. Bioorg Med Chem Lett 2002;12:2229-31
107. Turos E, Long TE, Heldreth B, et al. N-Thiolated β-lactams: a new family of anti-Bacillus agents. Bioorg Med Chem Lett 2006;16:2084-90
108. Revell KD, Heldreth B, Long TE, et al. N-thiolated β-lactams: studies on the mode of action and identification of a primary cellular target in Staphylococcus aureus. Bioorg Med Chem 2007;15:2453-67
109. Turos E, Shim JY, Wang Y, et al. Antibiotic-conjugated polyacrylate nanopartides: new opportunities for development of anti-MRSA agents. Bioorg Med Chem Lett 2007;17:53-6
110. Abeylath SC, Turos E, Dickey S, Lim DV. Glyconanobiotics: novel carbohydrated nanoparticle antibiotics for MRSA and Bacillus anthracis. Bioorg Med Chem 2007;16:2412-8
111. Fleming A. Penicillin. Nobel lecture; 11 December 1945
112. Harbarth S, Samore MH. Antimicrobial resistance determinants and controls. Emerg Infect Dis 2005;11:794-801
113. Lewis K. Persister cells, dormancy, and infectious disease. Nat Rev Microbiol 2007;5:48-56